AzTrials
AzTrials

AnesthesiaNCT02531139

The Effect of Blood Pressure on Cerebral Perfusion During Vascular Surgery

A study testing MAP maintained at 80 mmHg and MAP maintained at 60 mmHg in people with Anesthesia and Peripheral Arterial Diseases, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Anesthesia reduces blood pressure and cerebral blood flow is normally considered to be maintained despite marked changes in blood pressure. Vascular surgical patients are often elderly, have high blood pressure and atherosclerosis and in these patients cerebral blood flow may decrease if blood pressure is reduced… Read more about this study

Who is it for?
Ages 19 years and older
Conditions the study is for
Anesthesia, Peripheral Arterial Diseases
What is being tested?
MAP maintained at 80 mmHg and MAP maintained at 60 mmHg
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteDenmark
Study dates
1 Mar 2017to Nov 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients undergoing one of the following vascular surgical interventions in general anesthesia: Infra-inguinal bypass, femoro-femoral cross-over bypass or iliofemoral bypass surgery.
  • Age > 18 years. Informed consent

Who cannot join

  • Use of monoamine oxidase inhibitors
  • Allergy to phenylephrine
  • Patients that cannot cooperate during examination
  • Dementia defined as Mini-Mental State Examination < 24
  • Anesthesia within the last 30 days
  • Alcohol consumption at or above 420 grams per week
Show all 9Show fewer
  • Lack of fluency in written and spoken Danish
  • Severe hearing and vision impairment
  • Neurological disease

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Rigshospitalet, Anæstesi og Operationsklinikken 2043

    Copenhagen Ø, 2100

Other trials in Denmark

About this study

Official title: The Effect of Blood Pressure on Cerebral Perfusion and Oxygenation During Vascular Surgery

Anesthesia reduces blood pressure and cerebral blood flow is normally considered to be maintained despite marked changes in blood pressure. Vascular surgical patients are often elderly, have high blood pressure and atherosclerosis and in these patients cerebral blood flow may decrease if blood pressure is reduced during anesthesia. The purpose of this study is to assess the effect of blood pressure for preservation of cerebral blood flow during anesthesia in vascular surgery. The hypothesis is that in vascular surgical patients, during anesthesia, cerebral blood flow is higher with blood pressure maintained at a higher level than that used in normal clinical practice.

Read the detailed description

Background: Induction of anesthesia reduces mean arterial pressure (MAP) and cerebral blood flow is normally considered to be maintained by cerebral autoregulation despite changes in MAP between 60 - 150 mmHg and standard of care during anesthesia is to maintain MAP above 60 mmHg. Vascular surgical patients are often elderly with hypertension and atherosclerotic manifestations that may impair cerebral autoregulation of importance for anesthesia-induced reduction in blood pressure.

Objective: To assess the effect of MAP for preservation of cerebral blood flow and oxygenation during vascular surgery.

Hypothesis: The primary hypothesis is that during general anesthesia in vascular surgical patients, cerebral blood flow velocity and oxygenation is higher with MAP maintained at 80-90 mmHg, compared with a MAP maintained at a minimum of 60 mmHg.

MAP is controlled in both groups using continuous infusion of phenylephrine. Phenylephrine is used as a tool in order to assess the effect of MAP on the cerebral circulation. In both groups, central blood volume is optimized by infusion of lactated Ringer´s solution using a goal directed fluid therapy following induction of anaesthesia and before commencement of phenylephrine infusion.

Trial size: The investigators will include 40 participants (2 x 20) in order to detect or reject a 20% difference in middle cerebral artery velocity with a type I error risk of 5% and a type II error risk of 20% (power at 80%). Interim analysis will be conducted after inclusion of 20 patients (2 x 10). Excluded patients will be replaced.

Being tested
MAP maintained at 80 mmHg, MAP maintained at 60 mmHg
Keywords
Cerebrovascular Circulation, Anesthesia, Blood pressure, Peripheral Arterial Diseases
Medical subject headings
Peripheral Arterial Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MAP maintained at 80 mmHgOther

    Intervention group, MAP is maintained at 80 - 90 mmHg during anesthesia using continuous infusion of phenylephrine.

  • MAP maintained at 60 mmHgOther

    Control group, MAP is maintained at minimum of 60 mmHg during anesthesia using continuous infusion of phenylephrine.

Study groups in NCT02531139
Study groupRoleWhat they receive
MAP maintained at 80 mmHgExperimentalDuring anesthesia MAP is maintained at 80 - 90 mmHg MAP using continuous infusion of phenylephrine.
Receives: Other: MAP maintained at 80 mmHg
MAP maintained at 60 mmHgActive comparatorDuring anesthesia MAP is maintained at minimum of 60 mmHg using continuous infusion of phenylephrine.
Receives: Other: MAP maintained at 60 mmHg

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Middle cerebral artery blood velocity

    Middle cerebral artery blood velocity measured in [cm/s] assessed by transcranial Doppler. Changes in middle cerebral artery blood velocity reflects changes in cerebral blood flow.

    Measured: During surgery

Secondary outcomes (5)
  1. Change in serum S100B as compared between subjects in the control- and intervention groups

    Serum concentrations of S100B, a marker of neuronal injury

    Measured: Blood is sampled 10 min prior to induction of anesthesia and at the end of surgery

  2. Change in serum neuron-specific enolase as compared between subjects in the control- and intervention groups

    Serum concentrations of neuron-specific enolase, a marker of neuronal injury

    Measured: Blood is sampled 10 min prior to induction of anesthesia and at the end of surgery

  3. Regional cerebral oxygenation as compared between subjects in the control- and intervention groups

    Frontal lobe oxygenation measured as the percentage of oxyhemoglobin of total hemoglobin [%] evaluated by near-infrared spectroscopy

    Measured: During surgery

  4. Cardiac output as compared between subjects in the control- and intervention groups

    Cardiac output measured in [l/min] evaluated by pulse contour analysis of the arterial blood pressure curve

    Measured: During surgery

  5. Stroke volume as compared between subjects in the control- and intervention groups

    Stroke volume measured in [ml/min] evaluated by pulse contour analysis of the arterial blood pressure curve

    Measured: During surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Aug 2015 (estimated)
  2. Study start1 Mar 2017 (estimated)
  3. Primary completionNov 2017 (estimated)
  4. Study completionNov 2017 (estimated)

Why it stopped: Study was not feasible.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02531139
Sponsor's protocol ID
NDOlesen
Status last verified
Sep 2017
First submitted
14 Aug 2015
Last updated
28 Sep 2017
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing MAP maintained at 80 mmHg and MAP maintained at 60 mmHg in people with Anesthesia and Peripheral Arterial Diseases, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 28 Sep 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Middle cerebral artery blood velocity (time frame: During surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in